2.Barateu, L_2017_Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmaco 3.https://www.takeda.com/newsroom/newsreleases/2024/tak-861-data-at-sleep-2024-on-narcolepsy-type-1/ 4.https://clinicaltrials.gov/study/NCT05687903 A Study of TAK-861 in Participants Wit...
药品名称 TAK-861 药品类别 创新药; 化药; 小分子; potential first-in-class; G蛋白偶联受体 靶点 orexin receptor 2 (OX2R) 作用机制 OX2R激动剂 药品简介 -- 研发机构 Takeda Pharmaceuticals 最高研发阶段 全球: III期临床 中国: I期临床 审评审批类型 -- 外置链接 -- 了解药物更多情报 ...
Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024. 武田計劃在其 2024 財年的上半年快速啓動 NT1 中 TAK-861 的全球三期試驗。 譯文內容由第三人軟體翻譯。 以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力...
Last week, Takeda Pharmaceutical reported a third-quarter 2023 core net profit of ¥235.9 billion, down 9.4% and 9.5% on constant currency. 上周,武田制药公布的2023年第三季度核心净利润为2359亿日元,按固定汇率下降9.4%和9.5%。 Read Next: Back To Back FDA Approval For Takeda Within Two Days,...
TAK-861 was synthesized by Takeda Pharmaceutical Company Limited. Modafinil was synthesized by LKT Laboratories, Inc. (St. Paul, MN, USA). Clomipramine and orexin peptides were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Peptide Institute Inc. (Osaka, Japan), respectively. [3H]-...
Takeda will present additional data from the Phase 2 trials and long-term extension (LTE) study of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), bei
2024年11月6日 武田制药(Takeda Pharmaceuticals)宣布,其在中国启动的两项TAK-861国际多中心3期临床研究已在中国药物临床试验登记与信息公示平台官网公示。这两项研究分别为评价TAK-861治疗发作性睡病伴猝倒的疗效和安全性的研究(试验登记号:CTR20243927),以及在患有选定中枢性睡眠过度疾病的受试者中开展的评价TAK-86...